e-tender for the procurement of drugs for rare diseases for the year 2024-25 , laronidase for injection 2.9mg/5ml , idurusulfase for iv use 6mg/3ml , agalsidase beta for iv use 35 mg , agalsidase alfa for iv use 3.5 mg , recombinant human growth hormone for injection [injectable pen with the needle] • recombinant growth hormone for daily injection • ready to use pen for subcutaneous injection • liquid/powder with reconstitution • needle for subcutaneous injection should be with the pen free of cost (minimum one needle per mg) (5mg pen with 5 needles) • should be available in different strengths • should be approved for gh deficiency, turner syndrome, noonan syndrome and prader willi syndrome by the government and international agencies.